The following article is a part of conference coverage from the American Academy of Allergy, Asthma & Immunology Annual Meeting, being held in Phoenix, Arizona, from February 25 to 28, 2022. Click here to read more of MPR‘s conference coverage.

In children with uncontrolled persistent type 2 asthma and comorbid allergic rhinitis (AR), dupilumab improved AR-related health-related quality of life (HRQoL) and asthma control, according to findings being presented at the American Association of Allergy, Asthma & Immunology (AAAAI) 2022 Annual Meeting, held in Phoenix, Arizona, from February 25 to 28.

Comorbid AR is common in children with asthma. Dupilumab blocks the central drivers of type 2 inflammation in multiple diseases. Researchers sought to assess the impact of dupilumab on asthma control in children with type 2 inflammatory asthma phenotype (baseline blood eosinophils ≥150 cells/µL or fractional inhaled nitric oxide [FeNO] ≥20 ppb) and coexisting AR by assessing the changes in total interviewer-administered 7-Item Asthma Control Questionnaire (ACQ-7-IA) scores and the AR-related HRQoL interviewer-administered Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ-IA).

In the VOYAGE trial, a 52-week, placebo-controlled, double-blind, randomized, phase 3 study (ClinicalTrials.gov Identifier: NCT02948959), 84.6% of children (6-11 years of age) with uncontrolled persistent asthma had a history of comorbid AR. At baseline, 99.6% of children globally had PRQLQ-IA scores greater than zero (>0), indicating that AR-related HRQoL was affected. Every 2 weeks, children in the study received dupilumab (100/200 mg by body weight) or matched placebo, with researchers assessing changes from baseline to week 52. Questionnaires administered included questions on nose and eye symptoms, activity limitation, practical problems, and other symptoms, with lower scores indicating better quality of life.

Dupilumab significantly improved total interviewer-administered 7-Item Asthma Control Questionnaire (ACQ-7-IA) scores (least squares mean difference [LSMD] vs placebo [95% CI]: -0.50 [-0.66, -0.34]; P <.0001), and PRQLQ-IA global (LSMD [95% CI]: -0.47 [-0.73, -0.20]; P <.001) and all domain scores (P <.05) in children with uncontrolled persistent asthma and coexisting AR by week 52.

Researchers concluded, “Dupilumab improved asthma control and AR-related HRQoL in children with uncontrolled persistent type 2 asthma with coexisting AR.”

Disclosure: Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.

Visit MPR’s conference section for complete coverage of the AAAAI 2022 Annual Meeting.

Reference

Fiocchi A, Phipatanakul W, Durrani S, et al. Dupilumab improves asthma control, and allergic rhinitis-related health-related quality of life in children with uncontrolled persistent asthma with comorbid allergic rhinitis. Presented at: American Academy of Allergy, Asthma & Immunology (AAAAI) 2022 Annual Meeting; February 25–28, 2022; Phoenix, AZ. Abstract 409

This article originally appeared on Pulmonology Advisor